(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
SpaceX launches Starlink satellites on its 150th Falcon 9 mission of the year- Top Frozen yogurt Flavor: Cast Your Vote!
- Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 6 Top Computer game Control center
- Independence from the rat race: How to Save and Contribute Shrewdly
- 5 Movies That Leaving an Imprint with Inventive Innovation
- The Best Computer games Ever
- Fundamental Monetary Guidance for Going into Business
- Exploring Programming Greatness: A Survey of \Easy to use Connection points\
